CSL Licenses Arcturus mRNA Technology, But COVID-19 Vaccine Remains Uncertain
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.
You may also be interested in...
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Novavax Hopes COVID-19/Flu Vaccine Combo Can Help It Keep Up With mRNA Leaders
Novavax recently slashed its revenues forecasts, but is hoping a two-in-one COVID-19 and flu combination could help it carve out space in the post-pandemic market.